A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 371,481 shares of VRTX stock, worth $176 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
371,481
Previous 333,142 11.51%
Holding current value
$176 Million
Previous $139 Million 25.04%
% of portfolio
0.21%
Previous 0.19%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $15.1 Million - $18.6 Million
38,339 Added 11.51%
371,481 $174 Million
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $23.5 Million - $25.8 Million
57,727 Added 20.96%
333,142 $139 Million
Q4 2023

Feb 08, 2024

BUY
$343.0 - $410.68 $7.32 Million - $8.76 Million
21,332 Added 8.4%
275,415 $112 Million
Q3 2023

Nov 07, 2023

BUY
$338.18 - $362.46 $7.19 Million - $7.7 Million
21,257 Added 9.13%
254,083 $88.4 Million
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $4.62 Million - $5.18 Million
14,709 Added 6.74%
232,826 $81.9 Million
Q1 2023

May 08, 2023

BUY
$283.23 - $323.1 $6.01 Million - $6.86 Million
21,230 Added 10.78%
218,117 $68.7 Million
Q4 2022

Feb 07, 2023

BUY
$285.76 - $321.48 $5.4 Million - $6.08 Million
18,898 Added 10.62%
196,887 $56.9 Million
Q3 2022

Nov 01, 2022

BUY
$273.83 - $305.53 $4.54 Million - $5.07 Million
16,591 Added 10.28%
177,989 $51.5 Million
Q2 2022

Aug 04, 2022

BUY
$234.96 - $292.55 $3.09 Million - $3.85 Million
13,151 Added 8.87%
161,398 $45.5 Million
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $2.67 Million - $3.15 Million
12,079 Added 8.87%
148,247 $38.7 Million
Q4 2021

Feb 07, 2022

BUY
$177.01 - $223.45 $3.49 Million - $4.41 Million
19,729 Added 16.94%
136,168 $30.3 Million
Q3 2021

Nov 04, 2021

BUY
$181.39 - $202.99 $2.06 Million - $2.3 Million
11,348 Added 10.8%
116,439 $21.1 Million
Q2 2021

Aug 06, 2021

BUY
$187.49 - $221.1 $523,847 - $617,753
2,794 Added 2.73%
105,091 $21.2 Million
Q1 2021

May 06, 2021

BUY
$207.02 - $241.31 $2.44 Million - $2.85 Million
11,792 Added 13.03%
102,297 $22 Million
Q4 2020

Feb 09, 2021

BUY
$207.01 - $276.09 $1.68 Million - $2.24 Million
8,116 Added 9.85%
90,505 $21.4 Million
Q3 2020

Nov 10, 2020

BUY
$255.65 - $303.1 $4.58 Million - $5.43 Million
17,917 Added 27.79%
82,389 $22.4 Million
Q2 2020

Aug 06, 2020

BUY
$225.48 - $295.8 $2.78 Million - $3.65 Million
12,344 Added 23.68%
64,472 $18.7 Million
Q1 2020

May 11, 2020

BUY
$199.77 - $247.81 $209,758 - $260,200
1,050 Added 2.06%
52,128 $12.4 Million
Q4 2019

Feb 05, 2020

BUY
$166.71 - $223.91 $1.09 Million - $1.46 Million
6,523 Added 14.64%
51,078 $11.1 Million
Q3 2019

Nov 12, 2019

BUY
$166.23 - $187.09 $303,369 - $341,439
1,825 Added 4.27%
44,555 $7.55 Million
Q2 2019

Aug 08, 2019

BUY
$164.61 - $190.37 $1.39 Million - $1.61 Million
8,454 Added 24.66%
42,730 $7.84 Million
Q1 2019

Apr 26, 2019

BUY
$163.73 - $194.7 $340,885 - $405,365
2,082 Added 6.47%
34,276 $6.31 Million
Q4 2018

Feb 08, 2019

SELL
$151.91 - $192.21 $374,306 - $473,605
-2,464 Reduced 7.11%
32,194 $5.27 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $179,806 - $206,617
-1,072 Reduced 3.0%
34,658 $6.68 Million
Q2 2018

Aug 09, 2018

BUY
$145.72 - $169.96 $7,577 - $8,837
52 Added 0.15%
35,730 $6.07 Million
Q1 2018

May 02, 2018

SELL
$151.6 - $177.13 $520,442 - $608,087
-3,433 Reduced 8.78%
35,678 $5.82 Million
Q4 2017

Feb 06, 2018

BUY
$137.28 - $155.55 $216,627 - $245,457
1,578 Added 4.2%
39,111 $5.95 Million
Q3 2017

Nov 01, 2017

BUY
$148.13 - $162.24 $5.56 Million - $6.09 Million
37,533
37,533 $5.71 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.